Business Wire

Canoga Perkins' SyncMetra ® Network Connectivity Solution Enables Enterprise AI at the Edge, Powered by AMD FPGAs

14.4.2025 17:00:00 CEST | Business Wire | Press Release

Share

Network connectivity solutions provider, Canoga Perkins today announced that its SyncMetra ultra-low, guaranteed latency offering for enterprise AI at the edge is powered by AMD Virtex™ UltraScale+™ FPGAs.

SyncMetra is Canoga Perkins' software-defined, IT-operated private 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for enterprise AI, industrial automation, and AR/VR applications. Providing performance and features that enable inference to take place on-premise, consolidating multiple sensor feeds and reducing total cost of ownership—the SyncMetra unlocks a new breed of Enterprise Edge AI applications.

Programmable, expandable, and software-defined, SyncMetra operates via a cloud-managed network orchestrator (SyncMetra Manager), access points, a SyncMetra switch, and a 5G operating system or core. This allows network owners and integrators to auto-provision network resources to enable several key applications.

Powered by AMD Virtex UltraScale+ FPGAs, SyncMetra brings engineered and bounded latency to market for time-critical applications, delivering the ability to optimally deploy networks and solutions for some of the most complex use cases facing enterprises today:

  • Enterprise Edge AI: SyncMetra unlocks new abilities to scale enterprise AI deployments for a wide spectrum of inference-at-the-edge use cases, including physical security, retail, quality assurance and predictive maintenance.
  • Industrial Automation: SyncMetra Private 5G with Time-Sensitive Networking (TSN) provides industrial network owners and integrators guaranteed,​ ultra-reliable low latency communication (URLLC) and packet delivery – and a programmable expandable alternative to Wi-Fi and current 5G for industrial automation use cases.
  • AR/VR: SyncMetra provides specialized training facilities and their integrators the ability to configure and deploy single-server, on-premises communications solutions capable of delivering robust, mission-specific experiences to multiple, free-moving participants.

“The increasing complexity of emerging networks within industrial automation, enterprise AI and beyond required a transformative solution built to address those challenges,” said Gilles Garcia, senior director of business lead communications group at AMD. “AMD Virtex UltraScale+ devices are designed with exactly this type of innovation in mind, and we are proud that this collaboration with Canoga Perkins’ SyncMetra platform will enable the delivery of scalable, reprogrammable, and reliable connectivity solutions to empower IT departments and network operators alike.”

“We recognized early on that industrial automation and enterprise AI were being held back by current wireless technologies and the complexity of deploying ultra-reliable, guaranteed latency networks,” said Malik Arshad, president of Canoga Perkins. “With this in mind, we purpose-built SyncMetra to address these challenges head-on, leveraging industry-leading AMD FPGAs to deliver a transformative solution that redefines what’s possible.”

About Canoga Perkins

Founded in 1965, privately held Canoga Perkins has a long history of providing mission-critical, secure communications to service providers, the military, government agencies, and utilities. With more than 150,000 active network elements operating in Tier 1 service provider networks, Canoga Perkins is differentiated by the telco reliability of its products and its ability to anticipate and nimbly act on emerging IT trends.

AMD, UltraScale+, Virtex and combinations thereof are trademarks of Advanced Micro Devices, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250414723827/en/

Contacts

Amber Flores
Canoga Perkins, Marketing
aflores@canogaperkins.net

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye